Although patients with T-cell phenotype lymphomas are generally accepted to have worse prognosis than B-cell phenotype lymphomas, the studies comparing outcomes after autologous stem cell transplantation (ASCT) between peripheral T-cell lymphomas (PTCLs) and with diffuse large B-cell lymphoma (DLBCL) are few. In this study, we compared outcomes after ASCT between 23 patients with PTCLs and 54 patients with DLBCL. Univariate analysis showed that the timing of ASCT, complete response (CR) at ASCT, favorable lactate dehydrogenase/performance/stage, low/low-intermediate (L-LI) International Prognostic Index (IPI) and L-LI age-adjusted IPI (aaIPI) at ASCT were significant predictors of both OS and EFS. Multivariate analysis showed that CR and L-LI aaIPI at ASCT were favorable for both OS (hazard ratio (HR), 0.34; 95% CI, 0.14-0.81; P ¼ 0.016 and HR, 0.27; 95% CI, 0.12-0.57; P ¼ 0.001) and EFS (HR, 0.38; 95% CI, 0.17-0.85; P ¼ 0.020 and HR, 0.36; 95% CI, 0.17-0.77; P ¼ 0.008). B-cell or T-cell phenotype, however, had no impact on OS (HR, 0.56; 95% CI, 0.27-1.18; P ¼ 0.126) or EFS (HR, 0.62; 95% CI,; P ¼ 0.206). In conclusion, when compared to patients with DLBCL, patients with PTCLs did not have inferior outcomes after ASCT. T-cell phenotype itself may not have an effect on outcomes of PTCL patients who underwent ASCT.
Introduction
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of neoplasms. Patients often present with advanced disease, and the neoplasms are characterized by widespread dissemination and aggressive behavior. Although the condition is potentially curable, relapse seems to be more common in patients with PTCLs than in those with B-cell lymphomas of similar histologic grade. [1] [2] [3] [4] T-cell lymphomas account for 7-10% of non-Hodgkin's lymphomas (NHLs) in Western countries, 1, 3, 4 compared to 20-30% of NHLs in East Asia, including Korea. [5] [6] [7] [8] Immunophenotype has been generally regarded as a prognostic factor in patients with T-cell or B-cell lymphoid malignancies. 2, 3, [9] [10] [11] [12] [13] [14] But, few clinical trials have assessed whether immunophenotype itself leads to poor outcomes and resistance to treatments. 7 One of the comparisons showed that the 5-year OS rates were 30-49% for diffuse large B-cell lymphoma (DLBCL) patients and o30% in PTCL patients. 3 But, in recent literature, T-cell immunophenotype itself had not an effect on response to conventional chemotherapy, PFS, or OS. 7, 15 Poor prognosis in patients with PTCLs was shown to have association with initial clinical factors, such as poor risk factors of International Prognostic Index (IPI), rather than immunophenotype itself. 7, 15 Several studies have compared outcomes after conventional chemotherapy in patients with PTCLs and DLBCL. 3, [9] [10] [11] [12] 16, 17 In addition, several studies have shown that autologous stem cell transplantation (ASCT) can improve the poor outcomes of patients with PTCLs. [18] [19] [20] [21] [22] [23] To extend these findings, we retrospectively compared outcomes in 23 patients with PTCLs and 54 patients with DLBCL who underwent ASCT. We evaluated the prognostic factors influencing patient survival in both groups, as well as the influence of immunophenotype on survival following ASCT.
Materials and methods

Patients
As a single-institution retrospective study, we searched the transplant registry of Asan Medical Center, Seoul, Korea, and identified 23 patients diagnosed with PTCLs according to the WHO classification over a 14-year period (1 August 1993 to 1 November 2006), 20 had peripheral T-cell lymphoma unspecified and 3 had angioimmunoblastic T-cell lymphoma, as assessed by a pathologist (JH). We also identified 54 patients diagnosed with DLBCL during the same period. Clinical data collected for each patient included age, sex, complete blood count, lactate dehydrogenase (LDH) level, Ann Arbor stage, performance status (PS), number and sites of extranodal (EN) involvement, date of diagnosis, type of salvage chemotherapy if performed, type of high-dose chemotherapy (HDT), the timing of ASCT (front-line or first relapse), infused CD34 þ cell count, disease status at ASCT, date of last follow-up, and clinical response before and after ASCT. Each patient was observed for a minimum of 10 months after ASCT.
Response criteria
Responses to initial induction chemotherapy, salvage chemotherapy and HDT were evaluated according to the Cheson criteria.
24 CR1/PR1 was defined as complete response/partial response to first-line chemotherapy. CR2/PR2 was defined complete response/partial response to second-line chemotherapy after relapse. Refractory disease included primary refractory disease or refractory relapse before ASCT. Response to HDT was assessed 1 and 3 months after ASCT. Routine follow-up by imaging analysis was performed every 3 months for the first year after HDT/ASCT, every 6 months for the next 2 years and then yearly or whenever clinically indicated.
Statistical analysis
All data were analyzed with the Statistical Package for the Social Sciences 14.0 (SPSS Inc., Chicago, IL, USA). EFS was calculated from the date of ASCT to the date of disease progression, relapse or death from any cause. OS was calculated from the date of ASCT to the date of death from any cause or date of last follow-up for survivors. The association between clinical characteristics and response was analyzed using the Fisher's exact test or the Pearson's w 2 method. Survival curves were analyzed by the Kaplan-Meier method. The log-rank test was used for comparison between individual clinical features and survival. Factors associated with survival by univariate analysis were incorporated into a Cox proportional hazard model for multivariate analysis. All analyses were two sided, and statistical significance was defined by a P-value o0.05.
Results
Patient characteristics
Clinical characteristics of the patient groups are summarized in Table 1 . The median age of patients in the PTCLs and DLBCL groups was 48 years (range, 18-68 years) and 48 years (range, 15-65 years), whereas the male/female ratios were 4.75:1 and 1.34:1 (P ¼ 0.034) respectively. There were no between-group differences in proportion of performed salvage chemotherapy or HDT regimens, the number of infused CD34 þ cells, the timing of ASCT as front-line therapy or after first relapse, or disease status at the time of ASCT. In addition, the two groups showed no significant differences in age at diagnosis, serum LDH level, Eastern Cooperative Oncology Group (ECOG) PS, Ann Arbor stage, EN involvement status or proportion in IPI risk groups. Table 2 ). Both groups showed no significant difference in proportions of responses (P ¼ 0.432). Among patients who did not attain CR after ASCT or relapsed following ASCT were 17 patients treated with chemotherapy (3 patients), radiation therapy (9 patients) or second ASCT (5 patients). Patients who were not adequate for further treatment were followed with clinical observation.
Survivals after ASCT
The 2-year EFS rates of the PTCLs and DLBCL groups were 43% (95% CI, 23-63%) and 40% (95% CI, 27-53%), respectively (P ¼ 0.833; Figure 1a ). The 2-year OS rate for these two groups were 41% (95% CI, 21-61%) and 46% (95% CI, 33-59%), respectively (P ¼ 0.769; Figure 1b ).
In patients who did not receive antitumor therapy following ASCT (n ¼ 60) with attained or sustained CR after ASCT, the 2-year EFS rates of the PTCLs and DLBCL groups were 60.2% (95% CI, 41.6-78.8) and 60.6% (95% CI, 33.6-87.6), respectively (P ¼ 0.503; Figure 2a ). The 2-year OS rates for these two groups were 71.8% (95% CI, 53.8-89.8%) and 59.8% (95% CI, 32.4-87.2%), respectively (P ¼ 0.205; Figure 2b ).
The patients with high-intermediate or high (HI-H) risk age-adjusted IPI (aaIPI) scores showed that the median EFS was 2.17 months (95% CI, 0.47-3.86) in DLBCL patients and 3.52 months (95% CI, 0.00-8.82) in PTCLs patients (P ¼ 0.004). The median OS was 2.89 months (95% CI, 1.27-4.51) and 6.9 months (95% CI, 0.00-15.26), respectively (P ¼ 0.001). In low/low-intermediate (L-LI) risk patients at ASCT, there was no significant difference in 2-year EFS (B cell vs T cell; 52.6 vs 52.7%, P ¼ 0.422) and OS (B cell vs T cell; 60.7 vs 51.3%, P ¼ 0.338).
Univariate analysis of prognostic factors
When we assessed factors prognostic for outcome in a pool of the two groups (Table 3) , univariate analysis showed that factors significantly associated with OS were the timing of ASCT (P ¼ 0.014), disease status at ASCT (Po0.001), LDH level at ASCT (Po0.001), PS at ASCT (Po0.001), Ann Arbor stage at ASCT (Po0.001), IPI scores at ASCT (Po0.001) and aaIPI scores at ASCT (Po0.001). Factors significantly associated with EFS were the timing of ASCT (P ¼ 0.006), disease status at ASCT (Po0.001), LDH level at ASCT (Po0.001), PS at ASCT (Po0.001), Ann Arbor stage (P ¼ 0.002), IPI (Po0.001) and aaIPI (Po0.001). Interestingly, immunophenotype was not prognostic for either EFS (P ¼ 0.833; Figure 1a ) or OS (P ¼ 0.769; Figure 1b) .
In subgroup analysis of patients who underwent ASCT as upfront therapy (CR1/PR1), there was no significant 
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Cumulative OS rate Comparison of PTCLs and DLBCL patients after ASCT BS Sohn et al difference in outcomes between the patients with B-cell and T-cell immunophenotype (EFS, P ¼ 0.395; OS, P ¼ 0.438), also in patients who underwent ASCT after relapse (CR2/ PR2), there was no statistical difference between the two immunophenotypes (EFS, P ¼ 0.110; OS, P ¼ 0.129).
Multivariate analysis of prognostic factors
Multivariate analysis showed that the timing of ASCT (upfront vs relapse; hazard ratio (HR), 0.50; 95% CI, 0.23-1.08; P ¼ 0.075), disease status at ASCT (CR vs not CR; HR, 0.34; 95% CI, 0.14-0.81; P ¼ 0.016) and aaIPI (L-LI vs HI-H; HR, 0.27; 95% CI, 0.12-0.57; P ¼ 0.001) were prognostic factors for OS in the two groups (Table 4 ). Table 1a ).
In Cox proportional hazard models stratified on the matched pairs, after adjustment with all seven variables above and propensity score, the immunophenotype still did not have significant association with patients' outcomes (EFS: HR, 0.81; 95% CI, 0.27-2.4; P ¼ 0.702 and OS: HR, 1.92; 95% CI, 0.66-5.6; P ¼ 0.233).
Discussion
In several studies assessing outcomes in patients who underwent ASCT, the role of ASCT was poorly defined in patients with PTCLs, 2 or ASCT did not benefit nonanaplastic T-cell NHL patients, who had higher relapse rate than B-cell NHL patients. 17, 18, 25 In other studies, however, ASCT had a beneficial effect in patients with nonanaplastic T-cell NHL. 16, 19, 20, 22, 23 Studies assessing the benefits of ASCT as consolidation or salvage chemotherapy for patients with PTCLs have found that ASCT enhanced EFS and/or OS, compared with sequential or conventional chemotherapy. 16, 19, 21, 23 In this report, we have shown that the outcomes of ASCT in patients with PTCLs were similar to those in patients with DLBCL, indicating that HDT/ASCT has clinical benefits in patients with PTCLs. Also, we have shown that the prognostic factors that had an effect on patient's outcomes were the timing of ASCT, disease status at ASCT, aaIPI at ASCT and not phenotype itself. Compared with previous studies, which showed that patients with anaplastic large cell lymphoma (ALCL) had comparable prognosis to those with B-cell lymphoma after ASCT, whereas patients with other PTCL subtypes had worse prognosis, 18, 22, 25 we found here that patients with PTCLs, even excluding the ALCL subtype, can benefit from ASCT.
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Cumulative OS rate CR status at ASCT has been found to be an independent prognostic factor for both EFS and OS. The benefit from ASCT was mostly concentrated in patients with CR/PR at ASCT as shown in Table 2 . This markedly different outcome in patients with or without CR at ASCT also indicated the need for novel treatment modalities to increase CR rate before ASCT and thus to improve overall clinical courses as previous studies. 18, 19, 26 Also, the timing of ASCT has been found to have an association with patient's outcome. Especially in PTCLs, when ASCT was performed as upfront in nine patients, the 1-year survival rate was 76.2±14.8%. But, when ASCT was performed after first relapse in 14 patients, 1-year survival rate was 28.6 ± 12.1% (P ¼ 0.005). Because about one-third of our patients had refractory disease at ASCT, our EFS and OS rates were lower than those in studies that predominantly included patients who attained CR at transplantation, 17, [19] [20] [21] 25 but higher than those in study predominantly included patients who were refractory or relapsed. 22 According to the previous reports, 19, 20 ,23 the patients in HI-H risk group seemed to have more benefit from ASCT than L-LI risk group. We evaluated the outcomes of both risk groups to see whether substantial differences existed in acquiring benefit from ASCT by immunophenotype. Although patients with PTCLs in HI-H risk group showed better outcomes than the patients with DLBCL in HI-H risk group (Po0.01), the number of patients in HI-H risk group was too small. Also, the median EFS and OS were similarly poor at both groups.
Some studies reported similar outcomes between B-and T-cell lymphomas after conventional chemotherapy, 7, 15 whereas many previous studies indicated that patients with T-cell lymphoma have a worse prognosis than patients with B-cell lymphoma, including response rate to chemotherapy. [9] [10] [11] [12] [13] [14] [15] 27 Because the disease status at ASCT of our DLBCL and PTCLs groups did not differ significantly, even including 14 DLBCL patients who received R-ESHAP regimen as salvage chemotherapy, the comparable disease status at ASCT may have resulted from bias, in that the larger proportion of chemosensitive patients tended to be included in the PTCLs than in the DLBCL group. However, because patients with PTCLs generally accepted to have a higher relapse rate than those with DLBCL, [1] [2] [3] [4] our results may show that ASCT benefits PTCLs patients by lowering the relapse rate. Also, there was no patient who received rituximab monotherapy as a post transplant therapy. Thus, the comparable survival rate observed in these two groups may indicate that immunophenotype has little effect on responders at ASCT. The nonsignificant difference in OS seen in Figure 2b may be due to early death (o3 months) of two patients in PTCLs group. The causes of death were systemic infection following relapse.
In this study, seven patients in DLBCL underwent BUCYE þ yttrium-90 ibritumomab tiuxetan treatment. When they were compared with pooled patients with DLBCL, the 1-year survival rate of BUCYE þ yttrium-90 ibritumomab tiuxetan arm was 71.4 ± 17.1% whereas that of pooled patients was 55.2 ± 6.8%, and the 1-year EFS of BUCYE þ yttrium-90 ibritumomab tiuxetan arm was 68.2 ± 9.9% whereas that of pooled patients was 44.1 ± 6.8%. Considering these results, although it is a nonconventional regimen, there would be little possibility that BUCYE þ yttrium-90 ibritumomab tiuxetan regimen did actually lead to worse outcomes in pooled DLBCL patients.
Although our study was retrospective in design, heterogeneous in therapy and included small number of patients, the DLBCL and PTCLs groups showed no significant differences in clinical characteristics including IPI parameters, disease status at ASCT, ASCT protocols and method of follow-up. To the best of our knowledge, there has been few case of direct comparison of ASCT outcomes in patients with DLBCL and PTCLs. But, in this study, direct comparison between two groups showed that T-cell phenotype was not an independent prognostic indicator of survival after ASCT.
In conclusion, outcomes after ASCT were comparable in patients with PTCLs and DLBCL. Factors prognostic of survival after ASCT included disease status, the timing of ASCT and aaIPI score at the time of ASCT, regardless of T-cell or B-cell immunophenotype. Thus, immunophenotype had no effect on survival, especially in patients who underwent ASCT, and survival rates after ASCT were comparable in patients with PTCLs and DLBCL, when both had similar clinical risk characteristics at ASCT.
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